Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM)
Journal of Clinical Oncology · 20.01.2024 · 42 (3) · 312-323
DOI: 10.1200/jco.23.00236 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.01.2024. Verfasst von Naveen S Vasudev und 26 weiteren Autor:innen. Beteiligte Einrichtung: Leeds Institute of Medical Research at St James's, University of Leeds, St James's University Hospital, Leeds, United Kingdom. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Cancer Research UK.
Abstract (Originalsprache)
PURPOSE Ipilimumab (IPI), in combination with nivolumab (NIVO), is an approved frontline treatment option for patients with intermediate- or poor-risk advanced renal cell carcinoma (aRCC). We conducted a randomized phase II trial to evaluate whether administering IPI once every 12 weeks (modified), instead of once every 3 weeks (standard), in combination with NIVO, is associated with a favorable toxicity profile. METHODS Treatment-naïve patients with clear-cell aRCC were randomly assigned 2:1 to receive four doses of modified or standard IPI, 1 mg/kg, in combination with NIVO (3 mg/kg). The primary end point was the proportion of patients with a grade 3-5 treatment-related adverse event (trAE) among those who received at least one dose of therapy. The key secondary end point was 12-month progression-free survival (PFS) in the modified arm compared with historical sunitinib control. The study was not designed to formally compare arms for efficacy. RESULTS Between March 2018 and January 2020, 192 patients (69.8% intermediate/poor-risk) were randomly assigned and received at least one dose of study drug. The incidence of grade 3-5 trAEs was significantly lower among participants receiving modified versus standard IPI (32.8% v 53.1%; odds ratio, 0.43 [90% CI, 0.25 to 0.72]; P = .0075). The 12-month PFS (90% CI) using modified IPI was 46.1% (38.6 to 53.2). At a median follow-up of 21 months, the overall response rate was 45.3% versus 35.9% and the median PFS was 10.8 months versus 9.8 months in the modified and standard IPI groups, respectively. CONCLUSION Rates of grade 3-5 trAEs were significantly lower in patients receiving modified versus standard IPI. Although 12-month PFS did not meet the prespecified efficacy threshold compared with historical control, informal comparison of treatment groups did not suggest any reduction in efficacy with the modified schedule.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Leeds Institute of Medical Research at St James's, University of Leeds, St James's University Hospital, Leeds, United Kingdom.
- Clinical Trials Research Unit, University of Leeds, Leeds, United Kingdom.
- Royal Marsden Hospital, London, United Kingdom.
- Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom.
- Addenbrooke's Hospital, Cambridge, United Kingdom.
- The Clatterbridge Cancer Centre, Liverpool, United Kingdom.
ORCID-Profile: Naveen S Vasudev, Gemma Ainsworth, Sarah Brown, Lisa Pickering, Richard Griffiths, Anand Sharma, Galina Velikova, Anthony Maraveyas, Bernadett Szabados, Rosamonde E Banks, Balaji Venugopal, Poulam Patel, Paul Nathan, Fiona J Collinson, Thomas Powles
Förderung
- Cancer Research UK
Zitieren
APA
Vasudev, N. S., Ainsworth, G., Brown, S., Pickering, L., Waddell, T., Fife, K., Griffiths, R., Sharma, A., Katona, E., Howard, H., Velikova, G., Maraveyas, A., Brown, J., Pezaro, C., Tuthill, M., Boleti, E., Bahl, A., Szabados, B., Banks, R. E., …, & Powles, T. (2024). Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM). Journal of Clinical Oncology, 42(3), 312-323. https://doi.org/10.1200/jco.23.00236
Vancouver
Vasudev NS, Ainsworth G, Brown S, Pickering L, Waddell T, Fife K, et al. Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM). Journal of Clinical Oncology. 2024;42(3):312-323. doi:10.1200/jco.23.00236
BibTeX
@article{Vasudev2024,
author = {Vasudev, Naveen S and Ainsworth, Gemma and Brown, Sarah and Pickering, Lisa and Waddell, Tom and Fife, Kate and Griffiths, Richard and Sharma, Anand and Katona, Eszter and Howard, Helen and Velikova, Galina and Maraveyas, Anthony and Brown, Janet and Pezaro, Carmel and Tuthill, Mark and Boleti, Ekaterini and Bahl, Amit and Szabados, Bernadett and Banks, Rosamonde E and Brown, Joanne and Venugopal, Balaji and Patel, Poulam and Jain, Ankit and Symeonides, Stefan N and Nathan, Paul and Collinson, Fiona J and Powles, Thomas},
title = {Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM)},
journal = {Journal of Clinical Oncology},
year = {2024},
volume = {42},
number = {3},
pages = {312--323},
doi = {10.1200/jco.23.00236}
}
EUVIMED